Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Roche receives CE mark for Elecsys pTau181

September 2025—Roche has received the CE mark for its Elecsys pTau181 test to measure phosphorylated tau 181 protein, an indicator of amyloid pathology. The test, developed in collaboration with Eli Lilly, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer’s disease as the cause of cognitive decline.
The CE mark for the test was based on data from a prospective, multicenter study that included 787 patients in the United States, Europe, and Australia. The study showed the test was able to rule out Alzheimer’s disease with a high negative predictive value of 93.8 percent, based on a 22.5 percent prevalence of amyloid positivity according to PET scans, and with 83.6 percent sensitivity.

Cepheid gets Health Canada license for Xpert HIV-1 Viral Load XC

September 2025—Cepheid has received a medical device license from Health Canada for its Xpert HIV-1 Viral Load XC, a next-generation extended-coverage test intended to aid in assessing HIV viral load levels. The test is designed for use on the company’s GeneXpert systems.

SehaMed, New Day Dx to launch ColoHealth in the Middle East

September 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East. Under the terms of the agreement, SehaMed will leverage its network of distributors across the Gulf Cooperation Council to introduce ColoHealth.

Vizgen, Hamamatsu partner to streamline spatial biology workflows

August 2025—Vizgen and Hamamatsu Photonics have entered a strategic partnership that integrates Hamamatsu’s MoxiePlex multiplex immunofluorescence imaging system with Vizgen’s reagent and assay portfolio. The companies plan to combine their expertise through validated In­SituPlex panels, coupled with MoxiePlex, as an integrated multiplexed proteomic biomarker offering capable of multisite deployments for translational and clinical research applications.

IDT unveils infectious disease research solutions

August 2025—Integrated DNA Technologies has unveiled its PrimeTime influenza kit and PrimeTime research pathogen panels. The influenza kit is a qPCR solution designed to amplify common influenza strains and targets influenza A, influenza A (H5N1), influenza B, and RNase. It includes an internal control for sample quality assessment, a premixed primer and probe set, PrimeTime 4x Broad-Range Master Mix, and direct amplification enhancer.

MRC Holland assay for Peutz-Jeghers gains EU IVDR certification

August 2025—MRC Holland announced that its Salsa MLPA Probemix P101 STK11 assay for the detection of Peutz-Jeghers syndrome received the CE mark for in vitro diagnostic use under IVDR regulation EU 2017/746. The probe mix detects copy number variations in the STK11 gene and has been updated with two improved and two newly added denaturation control probes that facilitate the detection of denaturation issues with exceptional sensitivity, according to a company press statement.

SSI Diagnostica acquires Gulf Coast Scientific

August 2025—SSI Diagnostica Group is acquiring Gulf Coast Scientific (Oldsmar, Fla.), which specializes in the development of urea breath testing for Helicobacter pylori, to further strengthen its gastrointestinal disease testing portfolio. SSI Diagnostica, headquartered in Denmark, acquired CTK Biotech (Poway, Calif.) in 2020 and TechLab (Blacksburg, Va.) in 2022. Jointly the group will have a total revenue of approximately $125 million.

Waters acquires Halo Labs

August 2025—Waters Corp. announced it has acquired Halo Labs. Halo Labs’ Aura platform, which features a highly differentiated technology that performs full spectrum particle analysis, is complementary to the Waters light-scattering detection solutions from its Wyatt Technology portfolio. The subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T cells for cell therapy. By acquiring Halo Labs, Waters said it will be able to integrate the emerging technology into new and existing large molecule development and QA/QC.

Randox unveils Evidence RABTA

August 2025—Randox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour. The analyzer offers seamless random access capabilities, allows users to assign samples as priority, and uses single-use tips for aspiration and dispensing. The time to first result is 36 minutes, with up to 44 results per sample. Walkaway time is up to 2.5 hours.

Qiagen launches QIAseq, QIAcuity products

August 2025—Qiagen announced a series of product and partnership updates, including a new set of QIAseq panels for comprehensive genomic profiling, a QIAcuity digital PCR kit and assays for cell and gene therapy quality control, and a free, limited version of the Human Somatic Mutation Database from the Qiagen Digital Insights bioinformatics business.

MARKETPLACE

TRENDING